Trial
NCT05930938
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Groupe Oncologie Radiotherapie Tete et Cou
Collaborators
—
Condition
Squamous Cell Carcinoma of the Head and Neck
Intervention
Xevinapant
Why stopped
toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-09